# EDGAR Filing Document

**Accession Number:** 0001770121
**File Stem:** 0001193125-26-216824
**Filing Date:** 2026-5
**Character Count:** 18805
**Document Hash:** f90783e8bcf33b9a6a78cf02d9fbaa4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-216824.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001193125-26-216824

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**EFFECTIVENESS DATE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sana Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001770121
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831381173
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295758
- **FILM NUMBER:** 26963456

**BUSINESS ADDRESS:**
- **STREET 1:** 188 EAST BLAINE STREET, SUITE 350
- **CITY:** SEATTLE
- **STATE:** WA
- **BUSINESS PHONE:** (206) 701-7914

**MAIL ADDRESS:**
- **STREET 1:** 188 EAST BLAINE STREET, SUITE 350
- **CITY:** SEATTLE
- **STATE:** WA

**As filed with the Securities and Exchange Commission on May 11, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Sana Biotechnology, Inc.
**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **83-1381173** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |
| **188 East Blaine Street, Suite 350**<br> **Seattle, Washington 98102** | **98102** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2021 Incentive Award Plan** 

**(Full Title of the Plan)** 

**Aaron M. Grossman** 

**Executive Vice President, Chief Legal Officer** 

**Sana Biotechnology, Inc.** 

**188 East Blaine Street, Suite 350** 

**Seattle, Washington 98102** 

**(206) 701-7914** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Tony Jeffries** 

**Jennifer Knapp** 

**Phillip McGill** 

**Wilson Sonsini Goodrich & Rosati, Professional Corporation** 

**650 Page Mill Road** 

**Palo Alto, CA 94304** 

**(650) 493-9300** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

Sana Biotechnology, Inc. (the "***Registrant***") is filing this Registration Statement on Form S-8 (this "***Registration Statement***") for the purpose of registering an additional 13,336,582 shares of common stock under the Registrant's 2021 Incentive Award Plan, as amended (the "***2021 Plan***"), for which registration statements of the Registrant on Form S-8 (File Nos. [333-287088](http://www.sec.gov/Archives/edgar/data/1770121/000119312525116015/d862893ds8.htm), [333-279219](http://www.sec.gov/Archives/edgar/data/1770121/000119312524134294/d834326ds8.htm), [333-271728](http://www.sec.gov/Archives/edgar/data/1770121/000119312523138359/d413459ds8.htm), [333-264846](http://www.sec.gov/Archives/edgar/data/1770121/000119312522146418/d310603ds8.htm), and [333-252862](http://www.sec.gov/Archives/edgar/data/1770121/000119312521032543/d120409ds8.htm)) are effective (the "***Prior Registration Statements***"), pursuant to the provisions of the 2021 Plan that provide for an automatic annual increase in the number of shares of common stock reserved for issuance thereunder. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3.** **Incorporation of Documents by Reference.** <br>

The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the Securities and Exchange Commission (the "***SEC***"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000119312526088215/sana-20251231.htm) (File No. 001-39941) for the fiscal year ended December 31, 2025, filed with the SEC on March 3, 2026 (the "  ***Annual Report*** ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) all other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as
amended (the "  ***Exchange Act*** "), since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the description of the Registrant's common stock contained in the Registrant's Registration
Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1770121/000119312521016261/d31871d8a12b.htm) (File No. 001-39941) filed with the
Commission on January 25, 2021, pursuant to Section 
12(b) of the Exchange Act, as updated and superseded by the description of the Registrant's common stock contained in [Exhibit 4.3](http://www.sec.gov/Archives/edgar/data/1770121/000119312526088215/sana-ex4_3.htm) to the Annual
Report, including any amendments or reports filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such Current Report that relate to such items) subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; *provided*, *however*, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8.** **Exhibits.** <br>

The exhibits to this Registration Statement are listed below and are incorporated herein by reference.

------

**EXHIBIT INDEX** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| <br>**Exhibit**<br> **Number** | <br>**Description** | **Schedule**<br> **Form** | **File Number** | **Exhibit** | **Filing Date** |
| 4.1 | [Form of Common Stock Certificate.](http://www.sec.gov/Archives/edgar/data/1770121/000119312521019984/d60414dex42.htm) | S-1/A | 333-252061 | 4.2 | January 28, 2021 |
|  5.1\* | [Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation.](d134015dex51.htm) |  |  |  |  |
|  23.1\* | [Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included in Exhibit 5.1).](d134015dex51.htm) |  |  |  |  |
|  23.2\* | [Consent of Independent Registered Public Accounting Firm.](d134015dex232.htm) |  |  |  |  |
|  24.1\* | [Power of Attorney (included on the signature page of this Registration Statement).](#sig) |  |  |  |  |
|  99.1(a) | [2021 Incentive Award Plan.](http://www.sec.gov/Archives/edgar/data/1770121/000119312524134294/d834326dex991a.htm) | S-8 | 333-279219 | 99.1(a) | May 8, 2024 |
|  99.1(b) | [First Amendment to 2021 Incentive Award Plan, dated as of December 8, 2021.](http://www.sec.gov/Archives/edgar/data/1770121/000156459022010539/sana-ex104b_14.htm) | 10-K | 001-39941 | 10.4(b) | March 16, 2022 |
|  99.1(c) | [Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.](http://www.sec.gov/Archives/edgar/data/1770121/000119312521019984/d60414dex104b.htm) | S-1/A | 333-252061 | 10.4(b) | January 28, 2021 |
|  99.1(d) | [Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.](http://www.sec.gov/Archives/edgar/data/1770121/000156459022010539/sana-ex104d_13.htm) | 10-K | 001-39941 | 10.4(d) | March 16, 2022 |
|  99.1(e) | [Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan.](http://www.sec.gov/Archives/edgar/data/1770121/000119312521019984/d60414dex104c.htm) | S-1/A | 333-252061 | 10.4(c) | January 28, 2021 |
|  99.1(f) | [Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.](http://www.sec.gov/Archives/edgar/data/1770121/000119312521019984/d60414dex104d.htm) | S-1/A | 333-252061 | 10.4(d) | January 28, 2021 |
|  107.1\* | [Filing Fee Table.](d134015dexfilingfees.htm) |  |  |  |  |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on May 11, 2026.

---

| | |
|:---|:---|
|  **SANA BIOTECHNOLOGY, INC.** | **SANA BIOTECHNOLOGY, INC.** |
|  By: | /s/ Steven D. Harr, M.D. |
|  | Steven D. Harr, M.D. |
|  | *President and Chief Executive Officer* |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven D. Harr, M.D. and Brian Piper, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement and any and all additional registration statements pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Steven D. Harr, M.D.<br> Steven D. Harr, M.D. | President, Chief Executive Officer, and Director (Principal Executive Officer) | May 11, 2026 |
| /s/ Brian Piper<br> Brian Piper | Executive Vice President, Chief Financial Officer (Principal Financial Officer) | May 11, 2026 |
| /s/ Susan D. Wyrick<br> Susan D. Wyrick | Senior Vice President, Finance and Accounting (Principal Accounting Officer) | May 11, 2026 |
| /s/ Hans E. Bishop<br> Hans E. Bishop | Chairman of the Board | May 11, 2026 |
| /s/ Joshua H. Bilenker, M.D.<br> Joshua H. Bilenker, M.D. | Director | May 11, 2026 |
| /s/ Richard Mulligan, Ph.D.<br> Richard Mulligan, Ph.D. | Director | May 11, 2026 |
| /s/ Robert Nelsen<br> Robert Nelsen | Director | May 11, 2026 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Alise S. Reicin, M.D.<br> Alise S. Reicin, M.D. | Director | May 11, 2026 |
| /s/ Robert L. Rosiello<br> Robert L. Rosiello | Director | May 11, 2026 |
| /s/ Michelle Seitz, CFA<br> Michelle Seitz | Director | May 11, 2026 |
| /s/ Patrick Y. Yang, Ph.D.<br> Patrick Y. Yang, Ph.D. | Director | May 11, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g134015g0506073219152.jpg) | Wilson Sonsini Goodrich & Rosati<br> Professional Corporation<br>650 Page Mill Road<br> Palo Alto, California 94304-1050<br>O: 650.493.9300<br> F: 866.974.7329 |

---

May 11, 2026

Sana Biotechnology, Inc.

188 East Blaine Street, Suite 350

Seattle, Washington 98102

---

| | |
|:---|:---|
| **Re:** | **Registration Statement on Form S-8** |

---

Ladies and Gentlemen:

At your request, we have examined the Registration Statement on Form S-8 (the "Registration Statement") to be filed by Sana Biotechnology, Inc., a Delaware corporation (the "Company"), with the Securities and Exchange Commission (the "Commission"), on or about the date hereof, relating to the registration under the Securities Act of 1933, as amended (the "Act"), of 13,336,582 shares of the Company's common stock, par value $0.0001 per share (the "Shares"), to be issued under the Company's 2021 Incentive Award Plan, as amended (the "2021 Plan"). As your legal counsel, we have reviewed the actions proposed to be taken by you in connection with the issuance and sale of the Shares to be issued under the 2021 Plan.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when issued and sold in the manner described in the 2021 Plan and pursuant to the agreements that accompany the 2021 Plan, will be legally and validly issued, fully paid and nonassessable.

\* \* \*

We hereby consent to the filing of this opinion as an exhibit to the above-referenced Registration Statement and to the use of our name wherever it appears in the Registration Statement and in any amendments thereto. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours,<br>/s/ Wilson Sonsini Goodrich & Rosati, P.C. |
| WILSON SONSINI GOODRICH & ROSATI |
| Professional Corporation |

---

AUSTIN BOSTON BOULDER BRUSSELS CENTURY CITY HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO

SALT LAKE CITY SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE

## Exhibit 23.2

**Exhibit 23.2** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Sana Biotechnology, Inc. 2021 Incentive Award Plan of our report dated March 3, 2026, with respect to the consolidated financial statements of Sana Biotechnology, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Seattle, Washington

May 11, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Sana Biotechnology, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common stock, $0.0001 par value per share, reserved for issuance pursuant to the 2021 Incentive Award Plan, as amended | Other | 13336582 | $3.34 | $44544183.88 | 0.0001381 | $6151.55 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $44544183.88  |  | $6151.55  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $6151.55  |

---

 **Offering Note** <br>

<sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), the registration statement to which this exhibit relates (the "Registration Statement") shall also cover any additional shares of common stock, par value $0.0001 per share ("Common Stock"), of Sana Biotechnology, Inc. (the "Registrant") that become issuable under the 2021 Incentive Award Plan, as amended (the "2021 Plan"), by reason of any stock dividend, stock split, recapitalization, or similar transaction effected without the Registrant's receipt of consideration that would increase the number of outstanding shares of Common Stock. The proposed maximum offering price per unit is estimated pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of $3.34 per share, which is the average of the high and low sale prices of Common Stock as reported on The Nasdaq Global Select Market on May 4, 2026. The amount registered represents additional shares of Common Stock reserved for issuance under the 2021 Plan as a result of the automatic increase in shares reserved thereunder on January 1, 2026 pursuant to the terms thereof.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---